Overview

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
0
Participant gender:
All
Summary
This randomized controlled trial investigates the effect of a single dose of glucagon-like peptide-1 (GLP-1) receptor agonist on cerebral blood flow velocity and cortical oxygination in humans without cerebrovascular disease. This study serves as a control for a similar study investigating the effect in stroke patients (ref. to EGRABIS1).
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Christina Kruuse
Treatments:
Exenatide
Glucagon
Glucagon-Like Peptide 1
Criteria
Inclusion Criteria:

- Person ≥ 50 years of age

- Has given written informed consent

Exclusion Criteria:

- Intracerebral haemorrhage

- Subdural / epidural hemorrhage

- subarachnoid haemorrhage

- previously major structural damage to the brain (eg. sequelae after large stroke or
brain surgery)

- Diabetes type 1

- Diabetes type 2

- Known atrial fibrillation

- > 50% stenosis of internal carotid

- Known allergy to GLP-1 receptor agonists

- Hepatic impairment (ALT> 3 x upper normal limit)

- Renal impairment (eGFR <30 ml / min)

- Inflammatory bowel disease

- Previous pancreatitis

- Heart failure (NYHA class 3-4)

- Pregnancy or lactation

- Patient not expected to co-operate to the investigations

- Visualization of the middle cerebral artery bilaterally by transcranial doppler not
possible